After finishing at $5.36 in the prior trading day, Caribou Biosciences Inc (NASDAQ: CRBU) closed at $5.37, up 0.19%. In other words, the price has increased by $+0.01 from its previous closing price. On the day, 2665891 shares were traded.
Ratios:
Our goal is to gain a better understanding of CRBU by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.97 and its Current Ratio is at 11.97. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 31, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $13.
On July 11, 2023, Truist started tracking the stock assigning a Buy rating and target price of $23.Truist initiated its Buy rating on July 11, 2023, with a $23 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRBU now has a Market Capitalization of 485.89M and an Enterprise Value of 184.17M. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.07 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 5.34 whereas that against EBITDA is -1.64.
Stock Price History:
Over the past 52 weeks, CRBU has reached a high of $8.59, while it has fallen to a 52-week low of $3.44. The 50-Day Moving Average of the stock is 6.36, while the 200-Day Moving Average is calculated to be 5.64.
Shares Statistics:
The stock has traded on average 1.66M shares per day over the past 3-months and 2.2M shares per day over the last 10 days, according to various share statistics. A total of 88.45M shares are outstanding, with a floating share count of 79.39M. Insiders hold about 12.10% of the company’s shares, while institutions hold 77.97% stake in the company. Shares short for CRBU as of Feb 29, 2024 were 9.39M with a Short Ratio of 5.65, compared to 10.12M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.62% and a Short% of Float of 11.14%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.45, while EPS last year was -$0.46. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.4 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.62 and -$2.03 for the fiscal current year, implying an average EPS of -$1.79. EPS for the following year is -$2.1, with 6 analysts recommending between -$1.43 and -$2.97.
